EU Referendum: EFPIA, Witty And Soriot Show Their Hands
This article was originally published in Scrip
Executive Summary
Pharmaceutical industry associations have until recently remained pretty quiet over the prospect of a British exit from the EU. But following the announcement that the referendum will be held on June 23, that seems to be changing.
You may also be interested in...
UK On A Knife Edge As EU Referendum Nears
With the UK about to go to the polls in a once-and-for-all decision on EU membership, the stakes for the life sciences sector are high. The effects of a Brexit would be far-reaching, not only for the industry but also for other key groups such as regulators, patients and researchers.
ABPI And Top Pharma Execs Come Out Against Brexit
The Association of the British Pharmaceutical Industry has formally come out in support of the UK remaining part of the EU, saying that a vote to leave in next month's referendum would lead to delays in the availability of new drugs, have a detrimental effect on collaboration in European drug research, and discourage inward investment by international drug firms.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.